Buprenorphine depot - Camurus

Drug Profile

Buprenorphine depot - Camurus

Alternative Names: Buprenorphine FluidCrystal® injection depot; CAM 2038

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Camurus
  • Developer Braeburn Pharmaceuticals; Camurus
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Opioid abuse
  • Phase III Pain

Most Recent Events

  • 18 Sep 2017 Planned Prescription Drug User Fee Act (PDUFA) date for Opioid abuse in USA (SC, once-monthly, once-weekly) is 2018-01-19
  • 18 Sep 2017 US FDA accepts NDA for buprenorphine depot for Opioid abuse for priority review
  • 26 Jul 2017 Preregistration for Opioid abuse in European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top